In vivo interferon-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae

John H. Rex, John E. Bennett, John I. Gallin, Harry L. Malech, Ellen S. DeCarlo, David A. Melnick

Research output: Contribution to journalArticle

Abstract

During the recently completed double-blind, placebo-controlled, randomized trial of recombinant interferon-γ (rIFN-γ) therapy in chronic granulomatous disease (CGD), a metabolic assay of neutrophil damage to Aspergillus fumigatus hyphae was used to monitor neutrophil function before and during therapy. In this assay, 5 × 104 conidia that had germinated into hyphae were exposed to 5 × 105, 15 × 105, or 50 × 105 CGD neutrophils. By analysis of variance, neutrophils from patients on rIFN-γ were found to produce significantly more damage to hyphae than those from the placebo group (P <.01). In subgroup analysis, this effect was best seen in the hyphae exposed to 50 × 105 CGD neutrophils, where neutrophils from patients receiving rIFN-γ produced significantly more damage to the hyphae than those from the placebo group (P <.05). In vivo rIFN-γ therapy improves the ability of CGD neutrophils to damage Aspergillus fumigatus hyphae in an in vitro assay.

Original languageEnglish (US)
Pages (from-to)849-852
Number of pages4
JournalJournal of Infectious Diseases
Volume163
Issue number4
StatePublished - Apr 1991
Externally publishedYes

Fingerprint

Chronic Granulomatous Disease
Hyphae
Aspergillus
Interferons
Neutrophils
Aspergillus fumigatus
Placebos
Therapeutics
Fungal Spores
In Vitro Techniques
Analysis of Variance
Randomized Controlled Trials

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Rex, J. H., Bennett, J. E., Gallin, J. I., Malech, H. L., DeCarlo, E. S., & Melnick, D. A. (1991). In vivo interferon-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. Journal of Infectious Diseases, 163(4), 849-852.

In vivo interferon-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. / Rex, John H.; Bennett, John E.; Gallin, John I.; Malech, Harry L.; DeCarlo, Ellen S.; Melnick, David A.

In: Journal of Infectious Diseases, Vol. 163, No. 4, 04.1991, p. 849-852.

Research output: Contribution to journalArticle

Rex, JH, Bennett, JE, Gallin, JI, Malech, HL, DeCarlo, ES & Melnick, DA 1991, 'In vivo interferon-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae', Journal of Infectious Diseases, vol. 163, no. 4, pp. 849-852.
Rex, John H. ; Bennett, John E. ; Gallin, John I. ; Malech, Harry L. ; DeCarlo, Ellen S. ; Melnick, David A. / In vivo interferon-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. In: Journal of Infectious Diseases. 1991 ; Vol. 163, No. 4. pp. 849-852.
@article{56c6e17625604162b55df062908abb86,
title = "In vivo interferon-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae",
abstract = "During the recently completed double-blind, placebo-controlled, randomized trial of recombinant interferon-γ (rIFN-γ) therapy in chronic granulomatous disease (CGD), a metabolic assay of neutrophil damage to Aspergillus fumigatus hyphae was used to monitor neutrophil function before and during therapy. In this assay, 5 × 104 conidia that had germinated into hyphae were exposed to 5 × 105, 15 × 105, or 50 × 105 CGD neutrophils. By analysis of variance, neutrophils from patients on rIFN-γ were found to produce significantly more damage to hyphae than those from the placebo group (P <.01). In subgroup analysis, this effect was best seen in the hyphae exposed to 50 × 105 CGD neutrophils, where neutrophils from patients receiving rIFN-γ produced significantly more damage to the hyphae than those from the placebo group (P <.05). In vivo rIFN-γ therapy improves the ability of CGD neutrophils to damage Aspergillus fumigatus hyphae in an in vitro assay.",
author = "Rex, {John H.} and Bennett, {John E.} and Gallin, {John I.} and Malech, {Harry L.} and DeCarlo, {Ellen S.} and Melnick, {David A.}",
year = "1991",
month = "4",
language = "English (US)",
volume = "163",
pages = "849--852",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - In vivo interferon-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae

AU - Rex, John H.

AU - Bennett, John E.

AU - Gallin, John I.

AU - Malech, Harry L.

AU - DeCarlo, Ellen S.

AU - Melnick, David A.

PY - 1991/4

Y1 - 1991/4

N2 - During the recently completed double-blind, placebo-controlled, randomized trial of recombinant interferon-γ (rIFN-γ) therapy in chronic granulomatous disease (CGD), a metabolic assay of neutrophil damage to Aspergillus fumigatus hyphae was used to monitor neutrophil function before and during therapy. In this assay, 5 × 104 conidia that had germinated into hyphae were exposed to 5 × 105, 15 × 105, or 50 × 105 CGD neutrophils. By analysis of variance, neutrophils from patients on rIFN-γ were found to produce significantly more damage to hyphae than those from the placebo group (P <.01). In subgroup analysis, this effect was best seen in the hyphae exposed to 50 × 105 CGD neutrophils, where neutrophils from patients receiving rIFN-γ produced significantly more damage to the hyphae than those from the placebo group (P <.05). In vivo rIFN-γ therapy improves the ability of CGD neutrophils to damage Aspergillus fumigatus hyphae in an in vitro assay.

AB - During the recently completed double-blind, placebo-controlled, randomized trial of recombinant interferon-γ (rIFN-γ) therapy in chronic granulomatous disease (CGD), a metabolic assay of neutrophil damage to Aspergillus fumigatus hyphae was used to monitor neutrophil function before and during therapy. In this assay, 5 × 104 conidia that had germinated into hyphae were exposed to 5 × 105, 15 × 105, or 50 × 105 CGD neutrophils. By analysis of variance, neutrophils from patients on rIFN-γ were found to produce significantly more damage to hyphae than those from the placebo group (P <.01). In subgroup analysis, this effect was best seen in the hyphae exposed to 50 × 105 CGD neutrophils, where neutrophils from patients receiving rIFN-γ produced significantly more damage to the hyphae than those from the placebo group (P <.05). In vivo rIFN-γ therapy improves the ability of CGD neutrophils to damage Aspergillus fumigatus hyphae in an in vitro assay.

UR - http://www.scopus.com/inward/record.url?scp=0025907998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025907998&partnerID=8YFLogxK

M3 - Article

C2 - 1901332

AN - SCOPUS:0025907998

VL - 163

SP - 849

EP - 852

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 4

ER -